Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay

Jia Fan, Yi Huang, Inez Finoulst, Hung jen Wu, Zaian Deng, Rong Xu, Xiaojun Xia, Mauro Ferrari, Haifa Shen, Ye Hu

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The significant mortality rate associated with metastatic melanoma, which exceeds the number of deaths attributed to the primary tumor, is primarily due to poor diagnosis and increased resistance to systemic therapy. Early detection and treatment of invasive melanoma are therefore crucial to increase survival rates. Low molecular weight proteins and peptides have garnered significant interest as biomarker candidates as they potentially represent a snap shot of pathological condition within the body and, by extension, the organism as a whole. We have developed a nanoporous silica-based platform to segregate the low molecular weight from the high molecular weight protein fraction to aid in the detection of peptides from serum samples using mass spectrometry. The combination of sample treatment with our platform, MALDI-TOF MS and following biostatistical analysis led to the discovery and identification of 27 peptides that are potential biomarkers associated with the development of pulmonary metastatic melanoma. We strongly believe our findings can assist to discover stage-specific peptide signatures and lead to more specific and personalized treatments for patients suffering from pulmonary metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)202-210
Number of pages9
JournalCancer Letters
Volume334
Issue number2
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Nanopores
Melanoma
Biomarkers
Lung
Peptides
Molecular Weight
Serum
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Therapeutics
Silicon Dioxide
Mass Spectrometry
Proteins
Survival Rate
Mortality
Neoplasms

Keywords

  • MALDI-TOF MS
  • Nanoporous silica chip
  • Peptide signatures
  • Principal component analysis
  • Pulmonary metastatic melanoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay. / Fan, Jia; Huang, Yi; Finoulst, Inez; Wu, Hung jen; Deng, Zaian; Xu, Rong; Xia, Xiaojun; Ferrari, Mauro; Shen, Haifa; Hu, Ye.

In: Cancer Letters, Vol. 334, No. 2, 01.07.2013, p. 202-210.

Research output: Contribution to journalArticle

Fan, Jia ; Huang, Yi ; Finoulst, Inez ; Wu, Hung jen ; Deng, Zaian ; Xu, Rong ; Xia, Xiaojun ; Ferrari, Mauro ; Shen, Haifa ; Hu, Ye. / Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay. In: Cancer Letters. 2013 ; Vol. 334, No. 2. pp. 202-210.
@article{dc0e2a79d1424d00a025a969f6abfea4,
title = "Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay",
abstract = "The significant mortality rate associated with metastatic melanoma, which exceeds the number of deaths attributed to the primary tumor, is primarily due to poor diagnosis and increased resistance to systemic therapy. Early detection and treatment of invasive melanoma are therefore crucial to increase survival rates. Low molecular weight proteins and peptides have garnered significant interest as biomarker candidates as they potentially represent a snap shot of pathological condition within the body and, by extension, the organism as a whole. We have developed a nanoporous silica-based platform to segregate the low molecular weight from the high molecular weight protein fraction to aid in the detection of peptides from serum samples using mass spectrometry. The combination of sample treatment with our platform, MALDI-TOF MS and following biostatistical analysis led to the discovery and identification of 27 peptides that are potential biomarkers associated with the development of pulmonary metastatic melanoma. We strongly believe our findings can assist to discover stage-specific peptide signatures and lead to more specific and personalized treatments for patients suffering from pulmonary metastatic melanoma.",
keywords = "MALDI-TOF MS, Nanoporous silica chip, Peptide signatures, Principal component analysis, Pulmonary metastatic melanoma",
author = "Jia Fan and Yi Huang and Inez Finoulst and Wu, {Hung jen} and Zaian Deng and Rong Xu and Xiaojun Xia and Mauro Ferrari and Haifa Shen and Ye Hu",
year = "2013",
month = "7",
day = "1",
doi = "10.1016/j.canlet.2012.11.011",
language = "English (US)",
volume = "334",
pages = "202--210",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay

AU - Fan, Jia

AU - Huang, Yi

AU - Finoulst, Inez

AU - Wu, Hung jen

AU - Deng, Zaian

AU - Xu, Rong

AU - Xia, Xiaojun

AU - Ferrari, Mauro

AU - Shen, Haifa

AU - Hu, Ye

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The significant mortality rate associated with metastatic melanoma, which exceeds the number of deaths attributed to the primary tumor, is primarily due to poor diagnosis and increased resistance to systemic therapy. Early detection and treatment of invasive melanoma are therefore crucial to increase survival rates. Low molecular weight proteins and peptides have garnered significant interest as biomarker candidates as they potentially represent a snap shot of pathological condition within the body and, by extension, the organism as a whole. We have developed a nanoporous silica-based platform to segregate the low molecular weight from the high molecular weight protein fraction to aid in the detection of peptides from serum samples using mass spectrometry. The combination of sample treatment with our platform, MALDI-TOF MS and following biostatistical analysis led to the discovery and identification of 27 peptides that are potential biomarkers associated with the development of pulmonary metastatic melanoma. We strongly believe our findings can assist to discover stage-specific peptide signatures and lead to more specific and personalized treatments for patients suffering from pulmonary metastatic melanoma.

AB - The significant mortality rate associated with metastatic melanoma, which exceeds the number of deaths attributed to the primary tumor, is primarily due to poor diagnosis and increased resistance to systemic therapy. Early detection and treatment of invasive melanoma are therefore crucial to increase survival rates. Low molecular weight proteins and peptides have garnered significant interest as biomarker candidates as they potentially represent a snap shot of pathological condition within the body and, by extension, the organism as a whole. We have developed a nanoporous silica-based platform to segregate the low molecular weight from the high molecular weight protein fraction to aid in the detection of peptides from serum samples using mass spectrometry. The combination of sample treatment with our platform, MALDI-TOF MS and following biostatistical analysis led to the discovery and identification of 27 peptides that are potential biomarkers associated with the development of pulmonary metastatic melanoma. We strongly believe our findings can assist to discover stage-specific peptide signatures and lead to more specific and personalized treatments for patients suffering from pulmonary metastatic melanoma.

KW - MALDI-TOF MS

KW - Nanoporous silica chip

KW - Peptide signatures

KW - Principal component analysis

KW - Pulmonary metastatic melanoma

UR - http://www.scopus.com/inward/record.url?scp=84878255633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878255633&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2012.11.011

DO - 10.1016/j.canlet.2012.11.011

M3 - Article

C2 - 23200677

AN - SCOPUS:84878255633

VL - 334

SP - 202

EP - 210

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -